Investigating how MEK proteins affect leukemia in children
A Molecular Approach to Dissecting MEK-Mediated Phosphorylation in Pediatric Leukemia
This study is looking at how certain proteins called MEK affect the behavior of cancer cells in children with acute lymphoblastic leukemia (ALL), with the goal of finding new ways to help kids whose treatment isn't working as well as it should.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11089600 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of MEK proteins in pediatric acute lymphoblastic leukemia (ALL), which is a common type of blood cancer in children. The study aims to explore how these proteins influence cancer cell behavior through a series of chemical signals that affect cell growth and survival. By examining the molecular mechanisms involved, researchers hope to identify new treatment strategies that could improve outcomes for children with ALL, especially those whose disease does not respond to standard therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with acute lymphoblastic leukemia.
Not a fit: Patients with other types of leukemia or those outside the specified age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for children with acute lymphoblastic leukemia, particularly for those with relapsed or refractory disease.
How similar studies have performed: Previous research has shown promise in targeting MAPK pathways in cancer treatment, indicating that this approach could lead to significant advancements in therapy.
Where this research is happening
Chicago, UNITED STATES
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Scheidt, Karl a — Northwestern University
- Study coordinator: Scheidt, Karl a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.